MA33178B1 - Pipéridines substituées comme antagonistes de ccr3 - Google Patents
Pipéridines substituées comme antagonistes de ccr3Info
- Publication number
- MA33178B1 MA33178B1 MA34225A MA34225A MA33178B1 MA 33178 B1 MA33178 B1 MA 33178B1 MA 34225 A MA34225 A MA 34225A MA 34225 A MA34225 A MA 34225A MA 33178 B1 MA33178 B1 MA 33178B1
- Authority
- MA
- Morocco
- Prior art keywords
- ccr3 antagonists
- present
- piperidines substituted
- pharmaceutically acceptable
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS SUBSTITUÉS DE FORMULE 1, DANS LAQUELLE A, R1, R2, R3 ET R4 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES ANTAGONISTES DE CCR3, PLUS PARTICULIÈREMENT DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN VECTEUR PHARMACEUTIQUEMENT ACCEPTABLE ET UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE D'AU MOINS L'UN DES COMPOSÉS DE LA PRÉSENTE INVENTION OU DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09157653 | 2009-04-08 | ||
EP09174917 | 2009-11-03 | ||
PCT/EP2010/054396 WO2010115836A1 (fr) | 2009-04-08 | 2010-04-01 | Pipéridines substituées comme antagonistes de ccr3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33178B1 true MA33178B1 (fr) | 2012-04-02 |
Family
ID=42561233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34225A MA33178B1 (fr) | 2009-04-08 | 2010-04-01 | Pipéridines substituées comme antagonistes de ccr3 |
Country Status (31)
Country | Link |
---|---|
US (3) | US8278302B2 (fr) |
EP (1) | EP2417120B1 (fr) |
JP (1) | JP5466246B2 (fr) |
KR (1) | KR101690979B1 (fr) |
CN (1) | CN102388032B (fr) |
AP (1) | AP2989A (fr) |
AR (1) | AR076228A1 (fr) |
AU (1) | AU2010233849B2 (fr) |
BR (2) | BRPI1013821B1 (fr) |
CA (1) | CA2753151C (fr) |
CL (1) | CL2011002197A1 (fr) |
CO (1) | CO6501183A2 (fr) |
DK (1) | DK2417120T3 (fr) |
EA (1) | EA021072B1 (fr) |
EC (1) | ECSP11011427A (fr) |
ES (1) | ES2613696T3 (fr) |
GE (1) | GEP20135863B (fr) |
HK (1) | HK1164295A1 (fr) |
HU (1) | HUE030787T2 (fr) |
IL (1) | IL214309A (fr) |
MA (1) | MA33178B1 (fr) |
MX (1) | MX2011010584A (fr) |
MY (1) | MY161903A (fr) |
NZ (1) | NZ594597A (fr) |
PE (1) | PE20120135A1 (fr) |
PL (1) | PL2417120T3 (fr) |
PT (1) | PT2417120T (fr) |
SG (2) | SG175079A1 (fr) |
TW (1) | TWI466880B (fr) |
UY (1) | UY32547A (fr) |
WO (1) | WO2010115836A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
CN104203231A (zh) * | 2011-12-01 | 2014-12-10 | 葛兰素集团有限公司 | 治疗和预防眼疾病的方法 |
AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
EP2881394B1 (fr) | 2012-07-31 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Composé hétérocyclique à cycles condensés |
TWI679978B (zh) * | 2013-07-24 | 2019-12-21 | 日商田邊三菱製藥股份有限公司 | 眼科疾病治療劑 |
KR20170038877A (ko) * | 2014-08-01 | 2017-04-07 | 누에볼루션 에이/에스 | 브로모도메인에 대하여 활성을 갖는 화합물 |
DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
CN109152866B (zh) * | 2016-03-31 | 2021-10-15 | 国立研究开发法人国立长寿医疗研究中心 | 牙科用前处理材料及牙组织再生试剂盒 |
US20200054622A1 (en) * | 2017-04-05 | 2020-02-20 | Alkahest, Inc. | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors |
BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
CN110650740A (zh) * | 2017-04-05 | 2020-01-03 | 万能溶剂有限公司 | 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物 |
JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤およびその使用方法 |
WO2019046186A1 (fr) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal apoptotique contenant des tétrazoles et méthodes d'utilisation de ceux-ci |
CN107602457A (zh) * | 2017-10-10 | 2018-01-19 | 重庆奥舍生物化工有限公司 | 一锅法合成6‑甲基‑2‑氨基‑异烟酸的方法 |
EP3694514A4 (fr) * | 2017-10-13 | 2021-07-07 | Alkahest, Inc. | Méthodes et compositions pour pour traiter un prurit, un xérosis et une maladie associée à l'aide d'inhibiteurs de ccr3 |
WO2019213239A1 (fr) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation |
EP3787621A4 (fr) * | 2018-05-02 | 2022-01-12 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant des tétrazoles et leurs méthodes d'utilisation |
AU2019271122A1 (en) | 2018-05-15 | 2020-11-12 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
WO2020041417A1 (fr) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation |
MX2021002967A (es) * | 2018-09-26 | 2021-08-11 | Alkahest Inc | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. |
US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020198214A1 (fr) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs procédés d'utilisation |
WO2023076679A1 (fr) | 2021-11-01 | 2023-05-04 | Alkahest, Inc. | Modulateurs de benzodioxane de leucotriène a4 hydrolase (lta4h) pour la prévention et le traitement de maladies liées au vieillissement |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7907121L (sv) * | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
WO1999037619A1 (fr) | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Antagonistes du recepteur de la chemokine et procedes d'emploi desdits antagonistes |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
EP1052992A1 (fr) * | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
DE10233366A1 (de) | 2002-07-23 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
MXPA06004304A (es) | 2003-10-24 | 2006-06-05 | Hoffmann La Roche | Antagonistas del receptor ccr-3. |
CN1946402A (zh) * | 2004-02-05 | 2007-04-11 | 先灵公司 | 用作ccr3拮抗剂的哌啶衍生物 |
WO2005095339A1 (fr) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines inhibiteurs de la dipeptidyl peptidase iv |
MXPA06013213A (es) | 2004-05-13 | 2007-02-08 | Boehringer Ingelheim Int | Nuevas amidas sustituidas del acido tiofencarboxilico, su obtencion y su uso como medicamentos. |
CN101048418A (zh) | 2004-10-07 | 2007-10-03 | 贝林格尔·英格海姆国际有限公司 | Pi3-激酶 |
JP2006137718A (ja) * | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
WO2006083390A2 (fr) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxine-3 dans l'oesophagite eosinophile |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
WO2006118256A1 (fr) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | Dérivés de 2-aminoquinazoline |
WO2006114371A1 (fr) | 2005-04-28 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Nouveaux composes destines au traitement de maladies inflammatoires |
US20090124636A1 (en) | 2006-04-12 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2010
- 2010-03-19 US US12/727,318 patent/US8278302B2/en not_active Ceased
- 2010-04-01 JP JP2011544062A patent/JP5466246B2/ja active Active
- 2010-04-01 GE GEAP201012448A patent/GEP20135863B/en unknown
- 2010-04-01 EA EA201101398A patent/EA021072B1/ru not_active IP Right Cessation
- 2010-04-01 HU HUE10712432A patent/HUE030787T2/en unknown
- 2010-04-01 PE PE2011001650A patent/PE20120135A1/es not_active Application Discontinuation
- 2010-04-01 AU AU2010233849A patent/AU2010233849B2/en active Active
- 2010-04-01 BR BRPI1013821-8A patent/BRPI1013821B1/pt active IP Right Grant
- 2010-04-01 NZ NZ594597A patent/NZ594597A/en unknown
- 2010-04-01 BR BR122019017002-9A patent/BR122019017002B1/pt active IP Right Grant
- 2010-04-01 AP AP2011005817A patent/AP2989A/xx active
- 2010-04-01 KR KR1020117023451A patent/KR101690979B1/ko active IP Right Grant
- 2010-04-01 MY MYPI2011004829A patent/MY161903A/en unknown
- 2010-04-01 SG SG2011072626A patent/SG175079A1/en unknown
- 2010-04-01 PL PL10712432T patent/PL2417120T3/pl unknown
- 2010-04-01 WO PCT/EP2010/054396 patent/WO2010115836A1/fr active Application Filing
- 2010-04-01 CN CN201080015048.XA patent/CN102388032B/zh active Active
- 2010-04-01 MX MX2011010584A patent/MX2011010584A/es active IP Right Grant
- 2010-04-01 MA MA34225A patent/MA33178B1/fr unknown
- 2010-04-01 CA CA2753151A patent/CA2753151C/fr active Active
- 2010-04-01 ES ES10712432.3T patent/ES2613696T3/es active Active
- 2010-04-01 EP EP10712432.3A patent/EP2417120B1/fr active Active
- 2010-04-01 PT PT107124323T patent/PT2417120T/pt unknown
- 2010-04-01 DK DK10712432.3T patent/DK2417120T3/en active
- 2010-04-01 SG SG10201401347QA patent/SG10201401347QA/en unknown
- 2010-04-07 TW TW99110771A patent/TWI466880B/zh active
- 2010-04-07 UY UY0001032547A patent/UY32547A/es not_active Application Discontinuation
- 2010-04-07 AR ARP100101174A patent/AR076228A1/es active IP Right Grant
-
2011
- 2011-07-27 IL IL214309A patent/IL214309A/en active IP Right Grant
- 2011-08-28 EC EC2011011427A patent/ECSP11011427A/es unknown
- 2011-09-06 CL CL2011002197A patent/CL2011002197A1/es unknown
- 2011-09-29 CO CO11127672A patent/CO6501183A2/es active IP Right Grant
-
2012
- 2012-05-15 HK HK12104764.2A patent/HK1164295A1/xx unknown
- 2012-08-28 US US13/596,225 patent/US8653075B2/en active Active
-
2014
- 2014-02-07 US US14/175,082 patent/USRE45323E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
MA31766B1 (fr) | Composés organiques | |
MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
MA30421B1 (fr) | Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA30476B1 (fr) | Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1 | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
ATE464304T1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonist n | |
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
MA34767B1 (fr) | Compositions et procédés pour la modulation de fxr | |
TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
MA31000B1 (fr) | Derives 2-aza-bicyclo[3.1.0]hexane | |
EA200601895A1 (ru) | 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
MA33384B1 (fr) | Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant | |
MA35184B1 (fr) | Antagonistes de trpv4 | |
MA32170B1 (fr) | Nouveaux derives d'aminomethylbenzene | |
ATE484505T1 (de) | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten | |
TN2010000130A1 (fr) | Derives de quinazolinedione, leur preparation et leurs applications therapeutiques |